NCT05691504 2026-03-18
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
6 trialsNCT07428486 2026-02-23
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04001777 2025-10-01
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting
NCT04210037 2022-07-12
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT04354727 2022-07-12
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Ascentage Pharma Group Inc.
Phase 1/2 Withdrawn
NCT03387332 2021-08-27
APG-1252 in Patients With SCLC or Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Terminated